Listed

Phio Pharmaceuticals Corp.

PHIONasdaqCIK 1533040HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$4.3m, Q2 FY2026
Net income−$4.1m, Q2 FY2026
Phio Pharmaceuticals Corp., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$k1,808Research and development, Q3 FY2023, three months to 2023-09-30$1.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figure1,007Research and development, Q4 FY2023, three months to 2023-12-31$1.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-31, accession 0001683168-25-002134. Derived: 12-month figure less the 9-month figure.Report this figure1,148Research and development, Q1 FY2024, three months to 2024-03-31$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure866Research and development, Q2 FY2024, three months to 2024-06-30$866.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001683168-25-006174.Report this figure644Research and development, Q3 FY2024, three months to 2024-09-30$644.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure985Research and development, Q4 FY2024, three months to 2024-12-31$985.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-05, accession 0001437749-26-007078. Derived: 12-month figure less the 9-month figure.Report this figure886Research and development, Q1 FY2025, three months to 2025-03-31$886.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure1,074Research and development, Q2 FY2025, three months to 2025-06-30$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure1,181Research and development, Q3 FY2025, three months to 2025-09-30$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure1,477Research and development, Q4 FY2025, three months to 2025-12-31$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-05, accession 0001437749-26-007078. Derived: 12-month figure less the 9-month figure.Report this figure2,793Research and development, Q1 FY2026, three months to 2026-03-31$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure3,082Research and development, Q2 FY2026, three months to 2026-06-30$3.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure
Operating income$k(2,776)Operating income, Q3 FY2023, three months to 2023-09-30−$2.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figure(1,899)Operating income, Q4 FY2023, three months to 2023-12-31−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001683168-25-002134. Derived: 12-month figure less the 9-month figure.Report this figure(2,209)Operating income, Q1 FY2024, three months to 2024-03-31−$2.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure(1,914)Operating income, Q2 FY2024, three months to 2024-06-30−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001683168-25-006174.Report this figure(1,590)Operating income, Q3 FY2024, three months to 2024-09-30−$1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure(1,674)Operating income, Q4 FY2024, three months to 2024-12-31−$1.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001437749-26-007078. Derived: 12-month figure less the 9-month figure.Report this figure(1,872)Operating income, Q1 FY2025, three months to 2025-03-31−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure(2,309)Operating income, Q2 FY2025, three months to 2025-06-30−$2.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure(2,505)Operating income, Q3 FY2025, three months to 2025-09-30−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure(2,534)Operating income, Q4 FY2025, three months to 2025-12-31−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001437749-26-007078. Derived: 12-month figure less the 9-month figure.Report this figure(4,167)Operating income, Q1 FY2026, three months to 2026-03-31−$4.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure(4,268)Operating income, Q2 FY2026, three months to 2026-06-30−$4.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure
Interest expense$knot reportednot reported(53.0)Interest expense, Q1 FY2024, three months to 2024-03-31−$53.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figurenot reportednot reportednot reported(125)Interest expense, Q1 FY2025, three months to 2025-03-31−$125.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figurenot reportednot reportednot reportednot reportednot reported
Income tax$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$k(2,780)Net income, Q3 FY2023, three months to 2023-09-30−$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figure(1,895)Net income, Q4 FY2023, three months to 2023-12-31−$1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001683168-25-002134. Derived: 12-month figure less the 9-month figure.Report this figure(2,154)Net income, Q1 FY2024, three months to 2024-03-31−$2.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure(1,846)Net income, Q2 FY2024, three months to 2024-06-30−$1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure(1,524)Net income, Q3 FY2024, three months to 2024-09-30−$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure(1,626)Net income, Q4 FY2024, three months to 2024-12-31−$1.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001437749-26-007078. Derived: 12-month figure less the 9-month figure.Report this figure(1,769)Net income, Q1 FY2025, three months to 2025-03-31−$1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure(2,166)Net income, Q2 FY2025, three months to 2025-06-30−$2.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure(2,392)Net income, Q3 FY2025, three months to 2025-09-30−$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure(2,371)Net income, Q4 FY2025, three months to 2025-12-31−$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001437749-26-007078. Derived: 12-month figure less the 9-month figure.Report this figure(4,003)Net income, Q1 FY2026, three months to 2026-03-31−$4.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure(4,138)Net income, Q2 FY2026, three months to 2026-06-30−$4.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure
Diluted EPS$ per share(10.25)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$10.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figurenot reported(0.47)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure(3.62)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$3.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001683168-25-006174.Report this figure(1.54)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$1.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figurenot reported(0.41)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure(0.45)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001683168-25-006174.Report this figurenot reportednot reportednot reportednot reported
Basic EPS$ per share(10.25)Basic EPS, Q3 FY2023, three months to 2023-09-30−$10.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figurenot reported(0.47)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.47 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure(3.62)Basic EPS, Q2 FY2024, three months to 2024-06-30−$3.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001683168-25-006174.Report this figure(1.54)Basic EPS, Q3 FY2024, three months to 2024-09-30−$1.54 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figurenot reported(0.41)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.41 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure(0.45)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure(0.44)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figurenot reported(0.34)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure(0.36)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure

Balance sheet

Cash and equivalents$13.0m, Q2 FY2026
Shareholders' equity$12.6m, Q2 FY2026
Phio Pharmaceuticals Corp., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m8.4Cash and equivalents, Q3 FY2023, at 2023-09-30$8.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figure8.5Cash and equivalents, FY2023, at 2023-12-31$8.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-31, accession 0001683168-25-002134.Report this figure6.5Cash and equivalents, Q1 FY2024, at 2024-03-31$6.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0001683168-24-003175.Report this figure4.7Cash and equivalents, Q2 FY2024, at 2024-06-30$4.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-14, accession 0001683168-24-005706.Report this figure5.4Cash and equivalents, Q3 FY2024, at 2024-09-30$5.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figure5.4Cash and equivalents, FY2024, at 2024-12-31$5.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-05, accession 0001437749-26-007078.Report this figure13.3Cash and equivalents, Q1 FY2025, at 2025-03-31$13.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure10.8Cash and equivalents, Q2 FY2025, at 2025-06-30$10.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0001683168-25-006174.Report this figure10.7Cash and equivalents, Q3 FY2025, at 2025-09-30$10.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure21.0Cash and equivalents, FY2025, at 2025-12-31$21.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure17.0Cash and equivalents, Q1 FY2026, at 2026-03-31$17.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure13.0Cash and equivalents, Q2 FY2026, at 2026-06-30$13.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure
Current assets$m9.3Current assets, Q3 FY2023, at 2023-09-30$9.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001683168-23-007809.Report this figure9.3Current assets, FY2023, at 2023-12-31$9.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0001683168-25-002134.Report this figure6.8Current assets, Q1 FY2024, at 2024-03-31$6.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001683168-24-003175.Report this figure5.3Current assets, Q2 FY2024, at 2024-06-30$5.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0001683168-24-005706.Report this figure5.9Current assets, Q3 FY2024, at 2024-09-30$5.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figure5.7Current assets, FY2024, at 2024-12-31$5.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-05, accession 0001437749-26-007078.Report this figure13.4Current assets, Q1 FY2025, at 2025-03-31$13.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure11.3Current assets, Q2 FY2025, at 2025-06-30$11.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001683168-25-006174.Report this figure11.5Current assets, Q3 FY2025, at 2025-09-30$11.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure21.5Current assets, FY2025, at 2025-12-31$21.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure17.4Current assets, Q1 FY2026, at 2026-03-31$17.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure14.3Current assets, Q2 FY2026, at 2026-06-30$14.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure
Total assets$m9.5Total assets, Q3 FY2023, at 2023-09-30$9.5m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001683168-23-007809.Report this figure9.4Total assets, FY2023, at 2023-12-31$9.4m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0001683168-25-002134.Report this figure6.9Total assets, Q1 FY2024, at 2024-03-31$6.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001683168-24-003175.Report this figure5.3Total assets, Q2 FY2024, at 2024-06-30$5.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0001683168-24-005706.Report this figure5.9Total assets, Q3 FY2024, at 2024-09-30$5.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figure5.7Total assets, FY2024, at 2024-12-31$5.7m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-05, accession 0001437749-26-007078.Report this figure13.4Total assets, Q1 FY2025, at 2025-03-31$13.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure11.3Total assets, Q2 FY2025, at 2025-06-30$11.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001683168-25-006174.Report this figure11.5Total assets, Q3 FY2025, at 2025-09-30$11.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure21.5Total assets, FY2025, at 2025-12-31$21.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure17.4Total assets, Q1 FY2026, at 2026-03-31$17.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure14.3Total assets, Q2 FY2026, at 2026-06-30$14.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure
Current liabilities$m2.3Current liabilities, Q3 FY2023, at 2023-09-30$2.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001683168-23-007809.Report this figure1.6Current liabilities, FY2023, at 2023-12-31$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0001683168-25-002134.Report this figure1.2Current liabilities, Q1 FY2024, at 2024-03-31$1.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001683168-24-003175.Report this figure1.5Current liabilities, Q2 FY2024, at 2024-06-30$1.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-14, accession 0001683168-24-005706.Report this figure0.9Current liabilities, Q3 FY2024, at 2024-09-30$919.0k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figure1.0Current liabilities, FY2024, at 2024-12-31$1.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001683168-25-006174.Report this figure1.3Current liabilities, Q1 FY2025, at 2025-03-31$1.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure1.2Current liabilities, Q2 FY2025, at 2025-06-30$1.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001683168-25-006174.Report this figurenot reportednot reportednot reportednot reported
Total liabilities$m2.3Total liabilities, Q3 FY2023, at 2023-09-30$2.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001683168-23-007809.Report this figure1.6Total liabilities, FY2023, at 2023-12-31$1.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0001683168-25-002134.Report this figurenot reportednot reportednot reported1.0Total liabilities, FY2024, at 2024-12-31$1.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-05, accession 0001437749-26-007078.Report this figure1.3Total liabilities, Q1 FY2025, at 2025-03-31$1.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure1.2Total liabilities, Q2 FY2025, at 2025-06-30$1.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001683168-25-006174.Report this figure1.7Total liabilities, Q3 FY2025, at 2025-09-30$1.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure1.3Total liabilities, FY2025, at 2025-12-31$1.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure1.0Total liabilities, Q1 FY2026, at 2026-03-31$950.0k. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure1.7Total liabilities, Q2 FY2026, at 2026-06-30$1.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m7.2Shareholders' equity, Q3 FY2023, at 2023-09-30$7.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figure7.7Shareholders' equity, FY2023, at 2023-12-31$7.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-05, accession 0001437749-26-007078.Report this figure5.6Shareholders' equity, Q1 FY2024, at 2024-03-31$5.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure3.8Shareholders' equity, Q2 FY2024, at 2024-06-30$3.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure4.9Shareholders' equity, Q3 FY2024, at 2024-09-30$4.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure4.7Shareholders' equity, FY2024, at 2024-12-31$4.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure12.2Shareholders' equity, Q1 FY2025, at 2025-03-31$12.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure10.1Shareholders' equity, Q2 FY2025, at 2025-06-30$10.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure9.8Shareholders' equity, Q3 FY2025, at 2025-09-30$9.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001437749-25-034857.Report this figure20.1Shareholders' equity, FY2025, at 2025-12-31$20.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure16.5Shareholders' equity, Q1 FY2026, at 2026-03-31$16.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure12.6Shareholders' equity, Q2 FY2026, at 2026-06-30$12.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure

Cash flow

Operating cash flow−$4.0m, Q2 FY2026
Capital expenditure$0, Q2 FY2026
Phio Pharmaceuticals Corp., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(2,900)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0001683168-24-008120. Derived: 9-month figure less the 6-month figure.Report this figure(2,370)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$2.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001683168-25-002134. Derived: 12-month figure less the 9-month figure.Report this figure(2,011)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure(1,777)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001683168-25-006174. Derived: 6-month figure less the 3-month figure.Report this figure(1,953)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001437749-25-034857. Derived: 9-month figure less the 6-month figure.Report this figure(1,371)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001437749-26-007078. Derived: 12-month figure less the 9-month figure.Report this figure(1,275)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$1.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure(2,540)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001437749-26-026271. Derived: 6-month figure less the 3-month figure.Report this figure(2,085)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001437749-25-034857. Derived: 9-month figure less the 6-month figure.Report this figure(2,079)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001437749-26-007078. Derived: 12-month figure less the 9-month figure.Report this figure(4,003)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure(4,035)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001437749-26-026271. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-14, accession 0001683168-24-008120. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-31, accession 0001683168-25-002134. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-14, accession 0001683168-25-006174. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001437749-25-034857. Derived: 9-month figure less the 6-month figure.Report this figure1.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001437749-26-007078. Derived: 12-month figure less the 9-month figure.Report this figure2.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure3.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$3.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001437749-26-026271. Derived: 6-month figure less the 3-month figure.Report this figure7.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$7.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001437749-25-034857. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001437749-26-007078. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001437749-26-015604.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001437749-26-026271. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)4.79m, Q2 FY2025
Phio Pharmaceuticals Corp., shares, quarterly
Line itemUnitQ3 FY20212021-09-30Q1 FY20222022-03-31Q2 FY20222022-06-30Q3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30
Diluted shares (weighted)m shares13.5Diluted shares (weighted), Q3 FY2021, three months to 2021-09-3013,534,560 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2022-11-10, accession 0001683168-22-007528.Report this figure1.1Diluted shares (weighted), Q1 FY2022, three months to 2022-03-311,130,344 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-05-11, accession 0001683168-23-003213.Report this figure1,138Diluted shares (weighted), Q2 FY2022, three months to 2022-06-301,138,227,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-08-10, accession 0001683168-23-005514.Report this figure1.1Diluted shares (weighted), Q3 FY2022, three months to 2022-09-301,138,571 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0001683168-23-007809.Report this figure1.1Diluted shares (weighted), Q1 FY2023, three months to 2023-03-311,142,213 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0001683168-24-003175.Report this figure0.2Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30192,054 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-14, accession 0001683168-24-005706.Report this figure0.3Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30271,129 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figure4.6Diluted shares (weighted), Q1 FY2024, three months to 2024-03-314,580,072 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure0.5Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30510,188 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001683168-25-006174.Report this figure1.0Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30990,033 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0001683168-24-008120.Report this figure4.3Diluted shares (weighted), Q1 FY2025, three months to 2025-03-314,307,264 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0001683168-25-003719.Report this figure4.8Diluted shares (weighted), Q2 FY2025, three months to 2025-06-304,794,857 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001683168-25-006174.Report this figure

Shares outstanding: 11.62mShares outstanding, period not labelled, at 2026-08-0411,617,250 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001437749-26-026271.Report this figure at Aug 4, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.